KRYS Krystal Biotech, Inc.
Stock · NasdaqGS · United States · Healthcare · US5011471027
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Krystal Biotech, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
300.88 USD
+0.21%
52-week range
192.52 – 382.54
Dividend yield—
Market cap8.9B
NowoTrade score
77 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:08. Information, not advice.
Results
Next results
16 Feb 2027
in 101 days · 08:00 · estimate 2.24
Last results
2.05 vs 1.92 estimated
02 Nov 2026 · Beat +6.9%
Beat the estimate
6 of 12
6 missed · 0 in line
Average surprise
+54.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 16 Feb 2027 08:00 | 2.24 | — | — | Upcoming |
| 02 Nov 2026 07:00 | 1.92 | 2.05 | +6.9% | Beat |
| 03 Aug 2026 07:00 | 1.91 | 1.79 | -6.5% | Miss |
| 04 May 2026 07:00 | 1.42 | 1.83 | +29.0% | Beat |
| 17 Feb 2026 07:00 | 1.61 | 1.70 | +5.8% | Beat |
| 03 Nov 2025 07:00 | 1.12 | 2.66 | +137.0% | Beat |
| 04 Aug 2025 07:00 | 1.44 | 1.29 | -10.2% | Miss |
| 06 May 2025 08:00 | 1.52 | 1.20 | -21.1% | Miss |
| 19 Feb 2025 07:00 | 1.85 | 1.53 | -17.4% | Miss |
| 04 Nov 2024 08:00 | 1.33 | 1.29 | -3.2% | Miss |
| 05 Aug 2024 08:00 | 0.99 | 0.93 | -5.9% | Miss |
| 06 May 2024 08:00 | 0.29 | 0.46 | +58.1% | Beat |
| 26 Feb 2024 07:00 | -0.25 | 0.96 | +479.2% | Beat |
| 06 Nov 2023 07:00 | -0.67 | -0.67 | +0.8% | In line |
| 07 Aug 2023 07:00 | -0.74 | -1.25 | -69.7% | Miss |
| 08 May 2023 08:00 | -1.37 | -1.76 | -28.8% | Miss |
| 27 Feb 2023 07:00 | -0.56 | -1.25 | -121.9% | Miss |
| 07 Nov 2022 07:00 | -1.26 | -1.17 | +7.0% | Beat |
| 08 Aug 2022 07:00 | -1.00 | -1.10 | -9.6% | Miss |
| 09 May 2022 16:00 | -1.06 | -1.99 | -87.7% | Miss |
| 28 Feb 2022 07:00 | -0.73 | -0.95 | -29.7% | Miss |
| 08 Nov 2021 07:00 | -0.74 | -0.70 | +5.2% | Beat |
| 09 Aug 2021 08:00 | -0.78 | -0.74 | +4.9% | Beat |
| 10 May 2021 08:00 | -0.56 | -0.74 | -32.1% | Miss |
| 01 Mar 2021 08:00 | -0.59 | -0.53 | +10.7% | Beat |
| 09 Nov 2020 06:00 | -0.46 | -0.49 | -7.3% | Miss |
| 10 Aug 2020 07:00 | -0.39 | -0.37 | +6.1% | Beat |
| 04 May 2020 06:00 | -0.39 | -0.31 | +21.5% | Beat |
| 10 Mar 2020 08:00 | -0.33 | -0.31 | +7.0% | Beat |
| 04 Nov 2019 08:00 | -0.40 | -0.25 | +37.0% | Beat |
| 05 Aug 2019 08:00 | -0.31 | -0.37 | -19.4% | Miss |
| 06 May 2019 08:00 | -0.33 | -0.29 | +12.1% | Beat |
| 12 Mar 2019 08:00 | -0.23 | -0.28 | -19.7% | Miss |
| 05 Nov 2018 08:00 | -0.26 | -0.26 | 0.0% | In line |
| 06 Aug 2018 08:00 | -0.34 | -0.22 | +35.3% | Beat |
| 07 May 2018 08:00 | -0.48 | -0.21 | +56.3% | Beat |
| 12 Mar 2018 12:00 | -0.23 | -0.26 | -13.0% | Miss |
| 13 Nov 2017 16:00 | -0.74 | -1.26 | -70.3% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 389.1M | +33.9% | 204.8M | 52.6% | 6.84 | +128.0% | 188.9M |
| 2024 | 290.5M | +473.0% | 89.2M | 30.7% | 3.00 | +669.2% | 119.2M |
| 2023 | 50.7M | — | 10.9M | 21.6% | 0.39 | +107.1% | -100.6M |
| 2022 | 0 | — | -140M | — | -5.49 | — | -153.5M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 29 Feb 2024 | 165.06 | 165.93 | 155.77 | 159.47 | -2.21% | 506,700 | |
| 28 Feb 2024 | 170.00 | 173.00 | 162.11 | 163.08 | -4.16% | 647,100 | |
| 27 Feb 2024 | 160.00 | 172.81 | 155.37 | 170.15 | +8.38% | 1,119,100 | |
| 26 Feb 2024 | 126.77 | 162.28 | 125.85 | 157.00 | +41.02% | 2,237,200 | |
| 23 Feb 2024 | 112.33 | 113.33 | 109.57 | 111.33 | -0.56% | 521,400 | |
| 22 Feb 2024 | 108.12 | 113.22 | 107.50 | 111.96 | +3.66% | 275,100 | |
| 21 Feb 2024 | 111.04 | 112.45 | 107.81 | 108.01 | -3.25% | 324,700 | |
| 20 Feb 2024 | 112.13 | 113.77 | 108.45 | 111.64 | -1.70% | 251,800 | |
| 16 Feb 2024 | 112.87 | 114.13 | 111.61 | 113.57 | +0.17% | 224,000 | |
| 15 Feb 2024 | 111.31 | 113.82 | 110.84 | 113.38 | +2.95% | 317,300 | |
| 14 Feb 2024 | 110.00 | 112.97 | 109.04 | 110.13 | +1.29% | 386,800 | |
| 13 Feb 2024 | 112.50 | 113.44 | 108.28 | 108.73 | -6.17% | 336,100 | |
| 12 Feb 2024 | 112.00 | 116.33 | 112.00 | 115.88 | +4.06% | 300,900 | |
| 09 Feb 2024 | 111.55 | 112.34 | 110.15 | 111.36 | +0.30% | 328,800 | |
| 08 Feb 2024 | 111.49 | 112.68 | 110.30 | 111.03 | -0.14% | 271,700 | |
| 07 Feb 2024 | 114.77 | 114.77 | 111.12 | 111.19 | -3.12% | 339,700 | |
| 06 Feb 2024 | 111.75 | 115.02 | 110.54 | 114.77 | +2.60% | 202,500 | |
| 05 Feb 2024 | 110.30 | 113.78 | 110.30 | 111.86 | +0.05% | 335,500 | |
| 02 Feb 2024 | 110.19 | 112.68 | 110.00 | 111.80 | +0.22% | 364,500 | |
| 01 Feb 2024 | 111.96 | 113.10 | 108.28 | 111.56 | +0.28% | 270,600 | |
| 31 Jan 2024 | 116.34 | 117.93 | 110.89 | 111.25 | -4.31% | 341,400 | |
| 30 Jan 2024 | 118.12 | 118.75 | 112.45 | 116.26 | -2.38% | 449,600 | |
| 29 Jan 2024 | 116.09 | 120.19 | 113.04 | 119.09 | +2.64% | 508,300 | |
| 26 Jan 2024 | 121.55 | 123.14 | 113.51 | 116.03 | -3.86% | 361,700 | |
| 25 Jan 2024 | 129.55 | 129.55 | 120.34 | 120.69 | -5.86% | 308,700 |
Page 28 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412 (opens in a new tab) Benzinga · 03 Nov 2026 14:38
- TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380 (opens in a new tab) Benzinga · 03 Nov 2026 11:48
- RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375 (opens in a new tab) Benzinga · 03 Nov 2026 11:02
- Krystal Biotech (KRYS) Stock Stays Above Fair Value After Buyback Plan (opens in a new tab) Simply Wall St. · 03 Nov 2026 06:11
- Earnings Beat May Change The Case For Krystal Biotech (KRYS) Stock (opens in a new tab) Simply Wall St. · 03 Nov 2026 05:10
- Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth? (opens in a new tab) Simply Wall St. · 03 Nov 2026 02:16
- Krystal Biotech Sinks 11% Despite Q3 Beat as Eye Trial Enrollment “Progressed Slower Than Initially Anticipated” (opens in a new tab) TIKR · 03 Nov 2026 00:51
- Krystal Biotech Inc (KRYS) (Q3 2026) Earnings Call Highlights: Vyjuvek Revenue Jumps 30% to ... (opens in a new tab) GuruFocus.com · 02 Nov 2026 23:03
- Krystal Biotech, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 02 Nov 2026 17:57
- Krystal Biotech (KRYS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 02 Nov 2026 16:58
- Krystal Biotech Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 02 Nov 2026 16:14
- Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 02 Nov 2026 15:20
- Krystal Biotech Analyst Says Stock Weakness 'Overblown' (opens in a new tab) Benzinga · 02 Nov 2026 14:43
- Krystal Biotech Shares Fall 3.7% Despite Q3 Earnings Beat and 30% Revenue Growth (opens in a new tab) InvestorsHub · 02 Nov 2026 13:42
- Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 02 Nov 2026 13:28
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 300.25 USD
- Market cap
- 8.9B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 15.3 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 19.1 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 5.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 40.88× | Weak | 31.09× |
| P/E (forward) | 32.6× | Weak | 14.98× |
| Price / book | 6.21× | Weak | 3.87× |
| Price / sales | 18.97× | Weak | 3.42× |
| EV / EBITDA | 34.9× | Weak | 13.09× |
| Free cash flow yield | 2.5% | Fair | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 94.3% | Good | 59.2% |
| Operating margin | 55.9% | Good | 7.8% |
| Net margin | 47.9% | Good | 3.4% |
| Return on equity | 17.5% | Good | 5.7% |
| Return on assets | 10.1% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 177% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.46× |
| Net debt / EBITDA | -3.94× | Good | 1.48× |
| Current ratio | 7.89× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow KRYS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.